Cadman

Cadman Wish List FB

Fundraising Goal: $15,000

$4,483 Raised: 30%
Cadman was diagnosed with the currently untreatable genetic disorder Creatine Transporter Deficiency (CTD) just before his 2nd birthday. At the time, he wasn't walking or talking yet, and while he has come a long way since then, at six years old, Cadman is still mostly non-verbal and faces many additional long-term challenges with the additional diagnoses that come along with CTD including intellectual disability, autism and epilepsy. We love and adore Cadman exactly the way he is yet we have hope for a better future for him thanks to the research efforts being led by ACD. Initial fundraising efforts have been very successful, and donations continue to be needed moving forward for continuing progress on gene therapy and drug development research. Your support means so much to our family and the entire community of people affected by Cerebral Creatine Deficiency Syndromes!

This year our family has decided to step up our own fundraising efforts by matching all donations made on Cadman’s behalf up to $15,000. Please help us honor this commitment by contributing to ACD’s Holiday Heroes fundraiser today!

Any contribution will make a big impact directly toward research efforts to find a treatment, and eventually a cure, for CTD—and we will personally guarantee that your contribution will be doubled until we reach our goal of $15,000. We need to get creatine into Cadman’s brain—this is very possible through the diverse pipeline of research areas ACD is funding, and it will take a lot of support to get there.

I’m particularly hopeful about two key areas that this year’s holiday giving fundraising will support:

  • CCDS Gene Therapy Awards: ACD’s gene therapy consortium awards have seeded the development of gene therapy for CTD. We want to further this work by identifying safe and effective ways to deliver a gene therapy cure for CTD
  • Drug Repurposing: Through the ACD fellowship awards, ACD has enabled researchers to study the CTD transporter and screen existing, safe drugs, that might rescue the function of a defective transporter. If successful, these efforts could lead to a faster, safer path to a clinical trial with a known drug.